Extended Data Fig. 8: Additional aITGB2 CAR-T evaluation.

a, Luciferase assay-based cytotoxicity analysis showing efficacy of 7065 based aITGB2 CAR-T with 1x – 4x Gly₄Ser (L1-L4) linker between heavy and light chain (Data from single experiment performed in triplicate). The luciferase signals of the cytotoxicity assays were normalized against untransduced T-cells of their respective E:T ratios. b, Bar plots showing cytotoxicity of aITGB2 CAR-T against primary AML patient samples. n = 3 technical replicates and 3 independent patient samples. E:T ratio was 3:1 with overnight incubation. Cells were gated on CD34+ cells for analysis. Gating strategy similar to Supplementary Information 1c. c, Cytokine profiling of aITGB2 CAR-T comparing against Empty CAR-T control upon pre vs post tumor exposure at E:T ratio of 1:1 for overnight incubation (Data from single experiment performed in triplicate). d–f, Representative flow cytometry-based histogram analysis showing activation markers (d), exhaustion markers (e) and memory markers (f) of CAR-T in pre vs post tumor exposure at E:T ratio of 1:1 for overnight incubation. Gating strategy similar to Supplementary Information 2d. Antibody dilutions used in d–f was 1:50. Only aITGB2 CAR-T manufacturing involved knocking out integrin β₂. All the statistical data in this figure are represented as mean ± SEM.